secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001551152-23-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q2 adj EPS $2.91 (-13.6%), rev $13.865B (-4.9%); raises FY adj EPS guidance to $10.90-$11.10
--------------------------------------------------------------------------------

- GAAP diluted EPS $1.14 (+123.5% YoY); adjusted diluted EPS $2.91 (-13.6% YoY); includes $0.15 IPR&D impact.
- Total net revenues $13.865B (-4.9% reported; -4.2% operational). Immunology $6.813B (-5.5%); Humira -25.2% to $4.012B.
- Skyrizi +50.4% to $1.883B; Rinvoq +55.1% to $918M. Neuroscience +13.6% to $1.885B; Vraylar +33.9%.
- Raised FY2023 adjusted diluted EPS guidance from $10.57-$10.97 to $10.90-$11.10; includes $0.23 IPR&D year-to-date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000028/0001551152-23-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000028/abbv-20230727.htm
  HTML page:      https://secwatch.observer/filing/0001551152-23-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer